Dihydrofolate Reductase Is a Valid Target for Antifungal Development in the Human Pathogen .

mSphere

Department of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA

Published: June 2020

AI Article Synopsis

  • The study explores the potential of dihydrofolate reductase (DHFR) as a target for developing new antifungal drugs, highlighting a gap in research on antifungal agents derived from the folate biosynthetic pathway.
  • Using a specific fungal strain, researchers found that the DHFR enzyme, Dfr1p, is crucial for the growth of this pathogen, and its inhibition significantly reduces the organism's virulence.
  • The results reveal that standard folate supplements are ineffective for this fungal strain, indicating that targeting DHFR could lead to novel therapies for severe invasive fungal infections.

Article Abstract

While the folate biosynthetic pathway has provided a rich source of antibacterial, antiprotozoal, and anticancer therapies, it has not yet been exploited to develop uniquely antifungal agents. Although there have been attempts to develop fungal-specific inhibitors of dihydrofolate reductase (DHFR), the protein itself has not been unequivocally validated as essential for fungal growth or virulence. The purpose of this study was to establish dihydrofolate reductase as a valid antifungal target. Using a strain with doxycycline-repressible transcription of ( strain), we were able to demonstrate that Dfr1p is essential for growth Furthermore, nutritional supplements of most forms of folate are not sufficient to restore growth when Dfr1p expression is suppressed or when its activity is directly inhibited by methotrexate, indicating that has a limited capacity to acquire or utilize exogenous sources of folate. Finally, the strain was rendered avirulent in a mouse model of disseminated candidiasis upon doxycycline treatment. Collectively, these results confirm the validity of targeting dihydrofolate reductase and, by inference, other enzymes in the folate biosynthetic pathway as a strategy to devise new and efficacious therapies to combat life-threatening invasive fungal infections. The folate biosynthetic pathway is a promising and understudied source for novel antifungals. Even dihydrofolate reductase (DHFR), a well-characterized and historically important drug target, has not been conclusively validated as an antifungal target. Here, we demonstrate that repression of DHFR inhibits growth of , a major human fungal pathogen. Methotrexate, an antifolate, also inhibits growth but through pH-dependent activity. In addition, we show that has a limited ability to take up or utilize exogenous folates as only the addition of high concentrations of folinic acid restored growth in the presence of methotrexate. Finally, we show that repression of DHFR in a mouse model of infection was sufficient to eliminate host mortality. Our work conclusively establishes DHFR as a valid antifungal target in .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316490PMC
http://dx.doi.org/10.1128/mSphere.00374-20DOI Listing

Publication Analysis

Top Keywords

dihydrofolate reductase
20
folate biosynthetic
12
biosynthetic pathway
12
antifungal target
12
reductase valid
8
reductase dhfr
8
valid antifungal
8
utilize exogenous
8
mouse model
8
repression dhfr
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!